BioSpace News Archive

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, announced that management will present at the 34th Annual ROTH Conference, which is being held March 13-15, 2022.

Palisade Bio, Inc. was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at TheNext Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting.

Infinity Pharmaceuticals, Inc. announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022.

Théa Pharma Inc. announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC.

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs, announced that its affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of Bentrio™ in COVID-19 patients.

Dr. Paul Gagne and the research team at Vascular Breakthroughs, LLC, and Vascular Care Connecticut have reached a key clinical development milestone in their participation in the DEXTERITY clinical trials with enrollment of their first patient.

In establishing the business, BMS completed a non-brokered private placement for proceeds of $500,000 on March 7, 2022.